PTEN loss in biopsy tissue predicts poor clinical outcomes in prostate cancer

International Journal of Urology

Volumn 21, Issue 12, 2014, Pages 1209-1214

  Mithal, Prabhakar ^a,d   Allott, Emma ^b,d   Gerber, Leah ^b   Reid, Julia ^c   Welbourn, William ^c   Tikishvili, Eliso ^c   Park, Jimmy ^c   Younus, Adib ^c   Sangale, Zaina ^c   Lanchbury, Jerry S ^c   Stone, Steven ^c   Freedland, Stephen J ^b,d  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b DUKE UNIVERSITY   (United States)

^c Myriad Genetic Laboratories   (United States)

^d DURHAM VA MEDICAL CENTER   (United States)

Author keywords

Biochemical recurrence; Castration resistant prostate cancer; Prostate cancer; Prostate cancer specific mortality; PTEN

Indexed keywords

PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PTEN PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER TISSUE; CASTRATION RESISTANT PROSTATE CANCER; FOLLOW UP; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TREATMENT RESPONSE; BIOPSY; EPIDEMIOLOGY; METABOLISM; MIDDLE AGED; MORTALITY; PROCEDURES; PROGNOSIS; PROSTATIC NEOPLASMS; SURVIVAL RATE; TIME; TRENDS; UNITED STATES;

BIOPSY; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NORTH CAROLINA; PROGNOSIS; PROSTATIC NEOPLASMS; PTEN PHOSPHOHYDROLASE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84925295476     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/iju.12571     Document Type: Article

References (26)

1. Epstein JI, Feng Z, Trock BJ, Pierorazio PM. Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades. Eur. Urol. 2012; 61: 1019-1024.
2. McMenamin ME, Soung P, Perera S, Kaplan I, Loda M, Sellers WR. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res. 1999; 59: 4291-4296.
3. Halvorsen OJ, Haukaas SA, Akslen LA. Combined loss of PTEN and p27 expression is associated with tumor cell proliferation by Ki-67 and increased risk of recurrent disease in localized prostate cancer. Clin. Cancer Res. 2003; 9: 1474-1479.
4. Dreher T, Zentgraf H, Abel U etal. Reduction of PTEN and p27kip1 expression correlates with tumor grade in prostate cancer. Analysis in radical prostatectomy specimens and needle biopsies. Virchows Arch. 2004; 444: 509-517.
5. Yoshimoto M, Cunha IW, Coudry RA etal. FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome. Br. J. Cancer 2007; 97: 678-685.
6. Schmitz M, Grignard G, Margue C etal. Complete loss of PTEN expression as a possible early prognostic marker for prostate cancer metastasis. Int. J. Cancer 2007; 120: 1284-1292.
7. Bismar TA, Yoshimoto M, Vollmer RT etal. PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer. BJU Int. 2011; 107: 477-485.
8. Reid AH, Attard G, Ambroisine L etal.; Transatlantic Prostate Group. Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer. Br. J. Cancer 2010; 102: 678-684.
9. Lotan TL, Gurel B, Sutcliffe S etal. PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients. Clin. Cancer Res. 2011; 17: 6563-6573.
10. Chaux A, Peskoe SB, Gonzalez-Roibon N etal. Loss of PTEN expression is associated with increased risk of recurrence after prostatectomy for clinically localized prostate cancer. Mod. Pathol. 2012; 25: 1543-1549.
11. McCall P, Witton CJ, Grimsley S, Nielsen KV, Edwards J. Is PTEN loss associated with clinical outcome measures in human prostate cancer? Br. J. Cancer 2008; 99: 1296-1301.
12. Han B, Mehra R, Lonigro RJ etal. Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression. Mod. Pathol. 2009; 22: 1083-1093.
13. De Velasco MA, Uemura H. Preclinical remodeling of human prostate cancer through the PTEN/AKT pathway. Adv. Urol. 2012; 2012: Article ID 419348. 12 pages.
14. Holcomb IN, Young JM, Coleman IM etal. Comparative analyses of chromosome alterations in soft-tissue metastases within and across patients with castration-resistant prostate cancer. Cancer Res. 2009; 69: 7793-7802.
15. Sircar K, Yoshimoto M, Monzon FA etal. PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer. J. Pathol. 2009; 218: 505-513.
16. Yoshimoto M, Joshua AM, Cunha IW etal. Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome. Mod. Pathol. 2008; 21: 1451-1460.
17. Choucair K, Ejdelman J, Brimo F, Aprikian A, Chevalier S, Lapointe J. PTEN genomic deletion predicts prostate cancer recurrence and is associated with low AR expression and transcriptional activity. BMC Cancer 2012; 12: 543.
18. Zafarana G, Ishkanian AS, Malloff CA etal. Copy number alterations of c-MYC and PTEN are prognostic factors for relapse after prostate cancer radiotherapy. Cancer 2012; 118: 4053-4062.
19. Freedland SJ, Humphreys EB, Mangold LA etal. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005; 294: 433-439.
20. Sangale Z, Prass C, Carlson A etal. A robust immunohistochemical assay for detecting PTEN expression in human tumors. Appl. Immunohistochem. Mol. Morphol. 2011; 19: 173-183.
21. Jia S, Gao X, Lee SH etal. Opposing effects of androgen deprivation and targeted therapy on prostate cancer prevention. Cancer Discov. 2013; 3: 44-51.
22. Song MS, Salmena L, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor. Nat. Rev. Mol. Cell Biol. 2012; 13: 283-296.
23. Wilt TJ, Brawer MK, Jones KM etal.; Prostate Cancer Intervention versus Observation Trial (PIVOT) Study Group. Radical prostatectomy versus observation for localized prostate cancer. N. Engl. J. Med. 2012; 367: 203-213.
24. Bedolla R, Prihoda TJ, Kreisberg JI etal. Determining risk of biochemical recurrence in prostate cancer by immunohistochemical detection of PTEN expression and Akt activation. Clin. Cancer Res. 2007; 13: 3860-3867.
25. Uzoh CC, Perks CM, Bahl A, Holly JM, Sugiono M, Persad RA. PTEN-mediated pathways and their association with treatment-resistant prostate cancer (Review). BJU Int. 2009; 104: 556-561.
26. Dong JT, Li CL, Sipe TW, Frierson HF Jr. Mutations of PTEN/MMAC1 in primary prostate cancers from Chinese patients. Clin. Cancer Res. 2001; 7: 304-308.